Background: Quiescence (G0) is a transient, cell cycle-arrested state. By entering G0, cancer cells survive unfavorable conditions such as chemotherapy and cause relapse. While G0 cells have been studied at the transcriptome level, how post-transcriptional regulation contributes to their chemoresistance remains unknown.
4 than the transcriptome alone. Our data reveal that DNA damage and stress signaling cause posttranscriptional alterations to produce a specialized gene expression program of pro-inflammatory, immune effectors that elicit chemosurvival.
Results

Serum-starvation or AraC treatment induces a quiescent and chemoresistant state of leukemic cells
To study clinical resistance in cancer, THP1 human AML cells were used as they show significant resistance to AraC (17) (cytosine arabinoside, Fig. S1A ), a standard anti-leukemic chemotherapeutic that targets DNA replication and thus proliferating cells (referred to as S+). Our data and others find that serum-starvation of THP1 (13) and other cell lines (1;8;11;18) induces a transient G0 state with known G0 and cell cycle arrest markers expressed ( Fig. 1C -D, S1B-C). Such serum-starvation induced G0 cells (referred to as SS) can be returned to the cell cycle upon serum addition (Fig. 1D) , verifying that they are quiescent and transiently arrested, unlike senescence or differentiation that are not easily reversed. We find that serum-starvation induced G0 SS cells show resistance to AraC chemotherapy.
Serum-grown S+ cells show a dose-dependent decrease in cell viability with AraC as expected, while SS cells persist, indicating their chemoresistance ( Fig. 1E ). Chemoresistant cancer cells include cancer stem cells and are a subpopulation that can be isolated from cancers after treatment with chemotherapy (2;6-10) that targets and eliminates S+ cells. We find that AraC-surviving THP1 (referred to as AraCS) cells are transiently arrested, like SS cells ( Fig. 1C -D, S1B); both AraCS and SS cells survive chemotherapy (Fig. 1E ). AraCS cells recover from their transient arrest upon AraC removal, proliferate ( Fig. 1D ), affirming the reversible G0 arrest state of chemoresistant cells, similar to SS cells (1;2;6-10).
G0 cells induced by SS or AraC have similar translatomes and proteome features that recapitulate gene expression profiles of in vivo chemoresistant leukemic and G0 models
To study post-transcriptionally regulated genes in G0, we profiled S+, SS cells and AraCS cells at the proteome, translatome and transcriptome levels using multiplexed quantitative proteomics (14), microarray analysis of heavy polysome-associated mRNAs (13;14;19), and total RNAs respectively ( Fig. 1A-B , S1D-F). Notably, we find that AraCS and SS cells show more similar gene expression profiles at the proteome and translatome levels, compared to transcriptome levels (Fig. 1F) . These data suggest that although these chemoresistant G0 cells are isolated via two different methods, they exhibit a common set of translatome and proteome, which could underlie their common characteristic of chemoresistance. These data indicate the relevance of examining both the translatome and transcriptome. Time-course translatome analysis revealed that SS G0 cells that were serum-starved for short periods (4 hours and 1 day), are distinct from SS G0 cells that were serum-starved for long periods (2 days and 4 days) ( Fig. S1E-F) . This is consistent with G0 as a continuum of assorted, arrested states (1), with temporal differences in underlying gene expression in early G0 compared to more homogeneity at late G0. SS and AraCS cells provide sufficient material to perform concurrent translatome, proteome and transcriptome profiling, compared to limited cells from in vivo resistance models where only transcriptomes were profiled. To test whether our G0 leukemic cells are relevant models to study chemoresistance and G0, gene expression profiles of AraCS and SS cells were compared to published transcriptome profiles of leukemia stem cells (LSC) from AML (16), dormant leukemic cells (LRC), and minimal residual disease (MRD) from chemotherapy surviving patient samples with acute lymphocytic leukemia (ALL) (15), as well as SS G0 fibroblasts (G0 HFF) (1). Importantly, we find that these published transcriptome signatures for in vivo chemoresistance and G0 models were significantly up-regulated in our SS and AraCS cells (referred to as resistant G0 leukemic cells), compared to S+ cells (Fig. 1G, S1G) . These data indicate that our resistant G0 leukemic cells are relevant models to study post-transcriptional regulation in chemoresistance as they have similar gene expression profiles to known transcriptional profiles from in vivo chemoresistance models.
Inhibition of canonical translation initiation in resistant G0 leukemic cells
We find overall protein synthesis is reduced at least 2-fold in AraCS, compared to S+ cells (Fig. 2B,   S1D ). Mechanistically, both rate-limiting steps in canonical translation initiation: recruitment of initiator tRNA, and mRNA cap recognition to recruit mRNAs to ribosomes are inhibited in G0 leukemic cells ( Fig. 2A ). Recruitment of initiator tRNA by eIF2 can be blocked by eIF2α phosphorylation as a stress response (13;20-25). We find that two eIF2 kinases, PKR and PERK, are activated and increase eIF2α phosphorylation ( Fig. 2C ) in G0 leukemic cells to inhibit canonical translation initiation. Consistent with our previous study (14), we observed dephosphorylation of 4E-BP ( Fig. 2C ) that inhibits cap-dependent translation initiation (26;27). Low mTOR activity is known to reduce translation of terminal oligopyrimidine tract (TOP) mRNAs such as ribosomal protein mRNAs (26;28;29), which is decreased in SS and AraCS cells ( Fig. 2D ). Decreased canonical translation can enable post-transcriptional regulation of specific genes, as observed previously (13;14) and lead to survival of G0 leukemic cells.
Global translatome analysis shows that inflammatory response genes are selectively translated in resistant G0 cancer cells
We measured the number of genes upregulated at the transcriptome, translatome and proteome levels in resistant G0 leukemic cells, compared to S+ cells. A significantly greater number of genes were upregulated in the translatome (580 genes, Table S1) and proteome (716 genes), compared to the transcriptome (318 genes) as shown in Fig. 2E . Importantly, 57% of upregulated genes were upregulated only in the translatome level ( Fig. 2F ) but not in the transcriptome, indicating post-transcriptional regulation. To investigate the biological function of these differentially expressed genes, gene ontology (GO) analysis was performed. Gene categories up-regulated in G0 translatomes include inflammatory response, immune modulators (receptors, antigen presentation and processing genes), cell adhesion, cell migration, lipid biosynthesis and cholesterol pathway genes ( Fig. 2G, S2E ). Downregulated genes include RNA processing and ribosome genes ( Fig. 2G ). To identify translationally upregulated genes, we measured the change in ribosome occupancy (RO) which is the ratio of polysomeassociated mRNA levels to total mRNA levels of each gene ( Fig. 2F , Venn diagram, heat map). We find 180 genes are translationally up-regulated above RNA level changes. These genes include antigen processing and presentation genes (30) (HLA-G, HLA-E) and immune receptors (CD47, Fig. 2F -G, S2I) (31-33) that regulate anti-tumor immune response and are associated with leukemic stem cells and resistance (34;35) .
We asked if this specific gene expression profile in resistant G0 leukemic cells is conserved in G0 cells of other tumors and normal cells. Therefore, global translatome profiling was conducted in G0 cells from four different cells lines: breast cancer (MCF7), liver cancer (HEP-G2), and osteosarcoma (U2OS) as well as non-cancerous fibroblasts (HFF) ( Fig. S2 ). Their translatome profiles were compared with resistant G0 leukemic cells, using GSEA and DAVID tools ( Fig. 2H -I, S2E-F). We find that 580 signature genes of resistant G0 leukemic cells (Table S1) were highly upregulated at the translatome level in G0 cells of these other cell types ( Fig. 2H ). As expected for these arrested cells, genes related to cell cycle, ribosome biogenesis, and DNA replication were commonly down-regulated ( Fig. 2I, S2E ). Importantly, inflammatory response genes were commonly up-regulated in cancer G0 cells but not normal G0 fibroblasts and do not significantly overlap with senescence-associated secretory pathway (SASP) ( Fig. 2I , S2G) (36;37), indicating a specific role in chemoresistant cancer cells.
Stabilization of ARE-bearing mRNAs is mediated by phosphorylation of TTP in resistant G0 leukemic cells
To identify cis-acting elements that mediate post-transcriptional regulation, the untranslated regions (UTRs) of differentially expressed genes were examined. We find that a GC-rich motif was enriched on 5′UTRs of translationally up-regulated genes and an AU-rich motif, on 5′UTRs of down-regulated genes, indicating that mRNAs with structured 5′UTRs are highly translated in G0 cells ( Fig. S3A-B ).
Importantly, 3'UTR AU-rich elements (AREs) are significantly enriched in the up-regulated translatome as well as transcriptome ( Fig 3A) . Furthermore, 30% of the translatome signature of G0 leukemic cells bear AREs (Table S2) AREs are important post-transcriptional regulatory elements that mediate rapid degradation and repression of mRNAs (38) . To understand how ARE mRNAs are highly expressed in G0 cells, we assessed the expression level of RNA-binding proteins. As expected, ARE-binding proteins known to cause mRNA decay or translation repression (39;40) are significantly reduced in G0 cells ( Fig. S3F ).
Additionally, the exosome and proteasome complexes that are implicated in ARE mRNA decay (41) However, we find that TTP is phosphorylated in SS and AraCS cells ( Fig. 3E , right). TTP phosphorylation is established to increase its levels (43) , and block its ability to destabilize ARE mRNAs, thus enabling ARE mRNA translation upon LPS treatment (44;45) . To test whether phosphorylation of TTP was required for the increased expression of ARE mRNAs in G0 leukemic cells, we generated non-phosphorylatable mutant TTP with key phosphorylation sites (Ser 52, 178) replaced by alanine (TTP-AA). TTP-AA has been shown to dominantly maintain ARE mRNA decay activity and reduce pro-inflammatory cytokines like TNFα in immune cells (43) (44) (45) . Expression of myc-tagged TTP-AA significantly reduced TNFα mRNA in both THP1 and K562 AraCS cells ( Fig. 3F ), overturning the decay inactivity of endogenous phospho-TTP. To determine the effect of TTP phosphorylation on the stability of ARE mRNAs, we measured the half-life of TNFα mRNA. Expression of TTP-AA mutant more significantly reduced the half-life of TNFα mRNA than TTP wild-type expressed in AraC-treated TTPdeficient macrophages 48 ( Fig 3G) . Furthermore, immunoprecipitation demonstrated that TTP-AA was associated with TNFα mRNA in AraCS cells ( Fig 3H) . These data indicate that inactivation of ARE mRNA decay by TTP phosphorylation (43;45;46) is a key regulator of expression of a pro-inflammatory gene, TNFα, in chemoresistant G0 cells. These results are consistent with our findings of increased levels and translation of ARE bearing mRNAs due to decreased ARE mRNA decay activity in G0 cells
The p38 MAPK-MK2 pathway phosphorylates TTP to promote expression of ARE-bearing mRNAs in resistant G0 leukemic cells
To investigate how TTP is phosphorylated in resistant G0 leukemic cells, we examined key signaling molecules involved in DNA-damage response (DDR) ( Fig. 4A ) that is induced by chemotherapies like AraC (47) (48) (49) (50) . As expected, AraC treatment induced rapid phosphorylation and activation of ATM ( Fig.   4B ). Importantly, we find that these conditions lead to phosphorylation and activation of p38 MAPK and its downstream effector, MAPKAPK2 (MK2) (51;52) ( Fig. 4B ). MK2 has been shown to phosphorylate TTP in macrophages treated with lipopolysaccharide (LPS) (43;45;46) . To examine whether the p38 MAPK-MK2 pathway phosphorylates TTP in resistant G0 leukemic cells, two different inhibitors of p38 MAPK were tested. Treatment with p38 MAPKα/β inhibitor, LY2228820 (LY) (52;53), or a pan-p38 MAPK inhibitor that targets all isoforms, BIRB796 (BIRB) (54), blocked phosphorylation of MK2 and prevented MK2-mediated TTP phosphorylation and reduces TNFα in AraCS cells (Fig. 4C ). These results suggest that p38 MAPK-MK2 phosphorylates TTP, resulting in enhanced expression of ARE mRNAs such as TNFα upon AraC treatment ( Fig. 4A ). To test if the p38 MAPK-MK2-TTP pathway regulates TNFα expression via its ARE, a firefly luciferase reporter bearing the 3′ UTR ARE of TNFα, 1 0 and as control, Renilla luciferase, were co-transfected. Luciferase activity of the ARE reporter increased by 2-fold in AraCS cells compared to S+ cells but not when p38 MAPK was inhibited ( Fig. 4D ). These data suggest that the p38 MAPK-MK2-TTP axis up-regulates expression of specific genes via AREs in G0 leukemic cells.
Phosphorylation of TTP induced by p38 MAPK-MK2 promotes chemoresistance
We noted that the p38 MAPK-MK2 pathway was rapidly activated to phosphorylate TTP within one day of SS or AraC treatment ( To confirm that phosphorylation of TTP induces chemoresistance, we over-expressed TTP mutant (TTP-AA) that cannot be phosphorylated by p38 MAPK-MK2, followed by AraC treatment. Importantly, we find that TTP-AA mutant expression reduces survival of AraC-resistant cells in THP1 and K562 leukemic cell lines ( Fig. 4H ). Furthermore, TTP-AA mutant, expressed in TTP-knockout macrophages, 1 1 induced apoptosis of AraC-surviving cells more significantly, compared to TTP wild-type ( Fig. 4I ).
Consistently, in multiple AML cell lines, early inhibition of p38 MAPK showed dramatically reduced chemosurvival but not in non-cancerous CD34+ cells ( Fig. 4J ). When treated with p38 MAPK inhibitor alone, viability of S+ cells in multiple AML cell lines remained unchanged, indicating the synergism of AraC and p38 MAPK inhibitors ( Fig. 4J ). Interestingly, p38 MAPK inhibition eliminated resistant cells more significantly at increasing concentrations of AraC (Fig. 4K ). This indicates that treatment with high concentrations of AraC would increase the number of cells induced into the resistant G0 state with strong phosphorylation of p38 MAPK-MK2-TTP. Conversely, even low concentrations of BIRB were sufficient to reduce chemoresistance ( Fig. S4C ). Unlike in solid tumors, where activation of p38 MAPK-MK2 induces resistance by arresting the cell cycle (38;51;52), p38 MAPK inhibition did not affect the cell cycle in AML cells ( Fig. S4D ). These data uncover rapid activation of a p38 MAPK-MK2 pathway that enables chemosurvival of G0 leukemic cells via inhibition of TTP activity.
TNFα, induced by phosphorylation of TTP, promotes chemoresistance
We demonstrated that TTP regulates the stability of ARE mRNAs such as TNFα in AraCS cells ( Fig.   3G ). Furthermore, inactivation of TTP allowed elevated TNFα translatome and protein levels in resistant G0 leukemic cells ( Fig 5B-C) . To assess the effect of TNFα on chemoresistance, we altered TNFα levels genetically and phamacologically in G0 cells ( Fig. 5A ). Induction of TNFα depletion prior to AraC effectively reduced AraC resistance, compared to depleting TNFα after AraC treatment, while no effect was observed with TNFα depletion alone without AraC (Fig. 5D ). In contrast, addition of recombinant TNFα enhanced survival of AraCS cells ( Fig. 5D ). TNFα-mediated chemoresistance is not due to arrested cell cycle as TNFα treatment without subsequent AraC does not alter the cell cycle 1 2 ( Fig. S5C ). These data suggest that phosphorylation of TTP and subsequent expression of TNFα, which are induced by p38 MAPK-MK2, are responsible for survival of G0 leukemic cells.
TNFα can also be inhibited pharmacologically with the drug pirfenidone (PFD) that can block TNFα translation in RAW264.7 cells and is used to treat idiopathic pulmonary fibrosis (52;55;56). In G0 leukemic cells, PFD reduced TNFα translatome and protein levels but not mRNA levels ( Fig. 5E, S5F ).
PFD treatment at least 18 hours prior to or along with AraC or SS significantly reduced viability of G0 leukemic cells but failed to reduce resistance when added after AraC treatment ( Fig. 5F, S5D ). As observed with p38 MAPK-MK2 activation ( Fig. 4A-B ), TNFα translatome level also is rapidly and dramatically increased upon SS treatment ( Fig. 5B ). These data indicate that activation of TNFα is an early event in G0 induction, which leads to resistance, and needs to be inhibited early to preclude downstream survival regulators. PFD treatment alone does not affect the viability of untreated S+ cells, indicating that the cytotoxic effect of PFD is specific to G0 leukemic cells ( SS decreases survival of G0 cells, while treatment after AraC or SS had no effect ( Fig. 5H ). These data suggest that the TNFα-NFκB inflammatory pathway is upregulated as an early survival pathway in G0 cells.
3 TTP regulates a pro-apoptotic JNK pathway via targeting DUSP1
We asked what other ARE mRNAs are targeted by TTP and affect cell survival. DUSP1 mRNA contains AREs in its 3' UTR. TTP has been shown to target DUSP1 mRNA for degradation upon LPS treatment of macrophages or dendritic cells (44;45;63) . To determine if TTP phosphorylation regulates DUSP1 in AraCS, we expressed TTP-AA mutant that is not phosphorylated in BMDM cells that lack TTP ( Fig. 6A ). Immunoprecipitation showed that TTP-AA associated with DUSP1 mRNA in AraCS cells Importantly, JNK inhibition reversed apoptosis of leukemic cells treated with AraC, LY and PFD, but did not affect the viability of untreated cells ( Fig. 6F ), indicating that inhibition of JNK pathway contributes to chemoresistance. Together, these results suggest that TTP-DUSP1 axis promotes chemoresistance via suppressing JNK-mediated apoptosis ( Fig. 6A ).
Co-inhibition of p38 MAPK and TNFα sensitizes resistant leukemic cells to AraC treatment
Although chemoresistant cells are sensitive to individual inhibition of either TNFα or p38 MAPK by PFD or LY respectively, a substantial proportion of cells still survived ( Fig. 4F, 5G ). Therefore, we asked if coinhibition of p38 MAPK and TNFα with LY and PFD respectively, could eliminate the remaining resistant cells. We find that individual treatment with either of LY or PFD prior to or along with AraC, reduces approximately 50% of surviving leukemic cells ( Fig. 7B ). Importantly, the combination of PFD and LY2228820 prior to AraC treatment−called PLA therapy−eliminates about 90% of chemoresistant cells in 1 4 multiple AML cell lines ( Fig. 7A-C ). Furthermore, PLA therapy decreased colony formation capacity of leukemic cells on methylcellulose by 10-fold, compared to AraC-treatment alone (Fig. 7D ). These data indicate a severe loss of stem cell capacity of leukemic cells treated with PLA therapy. In contrast, in the absence of AraC treatment, the combination of PFD and LY2228820 did not affect cell viability, apoptosis and colony formation capacity, indicating the synergistic effect between AraC and anti-inflammatory drugs ( Fig. 7B-D) . Despite the fact that stromal niche cells have been shown to protect leukemic cells from chemotherapy (65), we find that AML cells co-cultured with stromal cells remained sensitive to PLA therapy ( Fig. S5E ). We investigated the molecular mechanism by which PLA therapy enhanced chemosensitivity. We find that LY treatment destabilizes TNFα mRNAs by TTP dephosphorylation (43) ( Fig. 3G, 4C ), while PFD suppresses translation of TNFα mRNA (56) ( Fig. 5E ). Therefore, in PLA therapy, TNFα remains more effectively blocked, compared to individual drug treatments ( Fig. 6E ). Furthermore, a pro-apoptotic JNK pathway was more significantly activated in cells treated with PLA therapy than singledrug treatments (Fig. 6E ). Together, these results suggest that PLA therapy reduces TNFα and promotes a pro-apoptotic JNK pathway, leading to apoptosis of chemoresistant cells.
PLA therapy reduces chemoresistance in primary AML cells ex vivo and in vivo
To test the anti-leukemic activity of PLA therapy in primary AML (66), primary cells from AML patients as well as two murine AML models driven by Hoxa9/Meis1 or MLL/AF9 (SI Methods), were used. When either p38 MAPK or TNFα was inhibited prior to AraC treatment, moderate apoptosis of chemoresistant cells was observed in primary AML cells ( Fig. 8A-B ). Importantly, co-inhibition of p38 MAPK and TNFα by PLA therapy (pre-treatment before AraC) significantly reduced AraC resistance in fourteen out of fifteen AML patient samples as well as in primary cells from two AML mouse models ex vivo ( Fig. 8A-B ). In contrast, the viability of normal CD34+ cells from healthy donors was not affected by treatment with LY or PFD ( Fig. 4J, 8A -B), consistent with clinical studies that have shown that PFD and LY have 1 5 acceptable safety and tolerance (53;55). To further investigate the therapeutic potential of PLA therapy in vivo, human AML cells expressing luciferase (MOLM13-Luc, SI Methods) were intravenously or subcutaneously injected into NSG mice. After confirmation of engraftment by measuring tumor volume or bioluminescent imaging (BLI), the mice were treated with PLA therapy or AraC for two weeks.
Consistent with ex vivo results ( Fig. 7B ), PLA therapy significantly decreased the leukemic burden and tumor volume by 6-fold, compared to AraC treatment alone ( Fig. 8C-D) . Next, primary Hoxa9/Meis1 or MLL/AF9 leukemia cells were generated as described previously (67) , and transplanted to second recipient mice. These mice were treated with PLA therapy or AraC. Consistently, BLI shows that PLA therapy eliminated 78% or 96% of chemoresistant cells in a dosage-dependent manner ( Fig. 8E -F) and extended mice survival ( Fig. 8H and S5G ). In the absence of AraC treatment, the combination of PFD and LY2228820 did not affect leukemic burden, suggesting that cytotoxic effects of this combination are limited to AraC-resistant cells, rather than proliferating cells ( Fig. 8G ). Together, these results suggest PLA therapy has potential for improving AraC-mediated apoptosis in AML.
Discussion
G0 cells are a transiently arrested, clinically relevant subpopulation in cancers (1;2;5-10). Our previous data and others, revealed altered gene expression mechanisms in G0 leukemic cells, at the posttranscriptional (8;12) and translational levels (13;14;18). This would lead to a distinct gene expression profile to enable G0 cell survival in harsh conditions. G0 cells are resistant to stress conditions like serum-starvation, with transient inhibition of apoptosis, and proliferation (1;11;18). Importantly, we find that serum-starved leukemic SS G0 cells exhibit chemoresistance (Fig. 1E) ; consistently, true chemosurviving AraCS cells are transiently arrested and chemoresistant ( Fig. 1D -E, S1B-C). In accord, we find that SS cells are similar in translatome and proteome to AraCS cells ( Fig. 1F ), indicating that consistent with their common features of G0 arrest and chemosurvival, they show similar post-1 6 transcription gene expression. Published transcriptional signatures of in vivo chemoresistance leukemic models (1;2;8;11;15;16), are also highly expressed in SS and AraCS cells ( Fig. 1G, S1G ). Thus, the common G0 resistance gene expression profile observed in AraCS and SS G0 cells likely comprises genes that control survival and resistance. These data revealed that in addition to known transcriptional profiles, altered post-transcriptional mechanisms in G0 resistant cells contribute to their unique gene expression profile that underlies their chemoresistance.
Our findings reveal the importance of DNA damage and stress signaling that can initiate a proinflammatory response that causes survival ( Fig. 4 ). Differential genomic instability in cancers would lead to subpopulations within a tumor with disparate DDR and stress signaling (47-49) that we find, enables their chemotherapy survival via pro-inflammatory cytokines. Cytokines upregulated in SS and AraCS cells include some SASP factors but also other unique cytokines (36;37) ( Fig. S2G ). This is consistent with similarities and differences between G0 and senescence (1): both show low mTOR activity but G0 shows reversible arrest, stem cell markers, low p53 and lack of senescence markers ( Fig. 2C -D, 2I, S1G) (14)-unlike senescence(18). These data indicate that a quiescence-and resistance-specific set of pro-inflammatory and signaling genes are expressed in these resistant cells 
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Increasing AraC, a nucleotide analog that inhibits replication (17), would activate DDR and downstream p38 MAPK signaling (47) (48) (49) and should lead to more cells expressing this inflammatory pathway that enables resistance. Consistently, increased AraC treatment leads to more cells in the inflammatory phase that can be targeted by LY to curb resistance (Fig. 4K ). Non-cancerous cells do not show this pathway ( Fig. 2I ) and are not affected by inhibitors ( Fig. 4J, 8A) . These data suggest that certain chemotherapies and stresses like serum-starvation induce stress signaling ( Fig. 4A -C) and enrich for resistant G0 cells-in addition to pre-existing subpopulations with genomic instability that trigger DDR and stress (47) (48) (49) . Importantly, this resistance mechanism can be blocked, not only in anti-inflammatory PFD (52;55;56) that precludes downstream TNFα expression (55;56) ( Fig. 5E )-prior to (and continued with) AraC chemotherapy-lead to effective loss of chemoresistance in multiple AML cell lines (Fig. 7B ), in tumors in vivo in AML mouse models ( Fig. 8C-G) , and in patient samples (Fig.   8A ), validating their ability to reduce resistance and tumors in vitro and in vivo. LY destabilizes TNFα mRNA by TTP dephosphorylation (Fig. 4C) (43) , while PFD suppresses TNFα selectively at the translation level (56) (Fig. S5F ) and thus enables PLA combination therapy to more effectively curb resistance than the individual drugs ( Fig. 7B, 8B) . Apart from its effect on TNFα translation, PFD blocks inflammation regulator (71;72) p38 MAPKγ that can be increased upon p38MAPKα/β inhibition, preventing feedback reactivation of inflammation, and enabling PLA combination therapy to remain more efficacious than the individual drugs. Therefore, the combination of PFD and LY suppresses the inflammatory and stress response more effectively in vitro and in vivo ( Fig. 7-8 ). Upon inhibition of p38 MAPK, in addition to reduction of TNFα and its downstream anti-apoptotic signals, we find the ARE bearing DUSP1 is reduced, leading to activation(63;64)of the JNK pathway(73) to promote apoptosis ( Fig. 6E-F) . These data indicate that blocking pro-inflammatory effectors-that are induced by chemotherapy mediated DNA damage and stress signaling-leads to increased chemosensitivity and decreased resistant cell survival.
Our findings revealed that these pro-inflammatory and signaling genes upregulated in G0, have AREs and other UTR sequences that regulate mRNA levels and translation ( Fig. 3A-C, S3A) . The ATM-p38 MAPK-MK2 axis stabilizes these ARE bearing pro-inflammatory cytokine and signaling mRNAs by phosphorylating ARE binding mRNA decay factor, TTP to prevent its mRNA decay activity on proinflammatory cytokine TNFα ( Fig. 3D -H, 4C-D) and signaling regulator, DUSP1 ( Fig. 6A-D) . In support, overexpression of TTP-AA-that cannot be phosphorylated and is a dominant active form that restores ARE mRNA decay (43-45)-decreases TNFα and DUSP1 expression ( Fig. 3F-G, 6A-D) , and thereby reduces chemoresistance ( Fig. 4H-I, 6E-F) . This is consistent with previous studies on AREs in cancers 1 9 (14; 38;43;74-77) . These data suggest that phospho-TTP level or TTP activity is an important regulator of inflammatory response mediated chemoresistance, which can be harnessed as a marker and target against AML resistance. Consistently, published in vivo leukemia resistance models show increased expression of TTP and ARE bearing genes (15;78), similar to our studies (Fig. 3A-E) . Our studies on TTP and ARE regulated immune and signaling modulators that promote chemoresistance, are consistent with recent findings of TTP regulation of PDL1 to mediate immunoresistance in solid tumors (79) . Importantly, inhibition of these pathways curtails chemoresistance and tumor survival in vivo in primary AML patients and tumor models ( Fig. 8) . Together, these pathways that are upregulated in resistant cells (Fig. 4A, 5A ) via chemotherapy and stress induced signaling-decrease canonical translation and permits non-canonical post-transcriptional regulation of specific genes (Fig.   S6 )-to promote chemosurvival of G0 cancer cells.
Conclusions
Our studies reveal that G0 leukemic cells are chemoresistant, indicating their clinical importance in cancer persistence. We find a specific proteomic and translation profile that is induced commonly between G0 cells and chemosurviving leukemic cells. We uncovered critical genes that are specifically 
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